Literature DB >> 12802502

Androgen receptor independent cardiovascular action of the antiandrogen flutamide.

Radu Iliescu1, Luciana A Campos, Wolfgang-Peter Schlegel, Ingo Morano, Ovidiu Baltatu, Michael Bader.   

Abstract

We have previously shown that flutamide (specific antagonist of the androgen receptor) has antihypertensive effects. In the present study we examined the mechanisms of flutamide action in the vasculature. The vascular effects of flutamide were assayed in aortae isolated from male or female Sprague-Dawley rats and from rats or mice lacking a functional androgen receptor ( tfm, testicular feminization mutation). The effect of flutamide on coronary flow was tested in isolated hearts. In addition, male hypertensive rats with tfm mutation were treated with flutamide, and blood pressure was monitored. Flutamide induced a relaxation of rat aortae from all the strains used (maximum relaxation at 10 microM: 51.3+/-5.2% of phenylephrine contraction) and increased the coronary flow. The aortic relaxation to flutamide was abolished by endothelium removal, or by inhibition of nitric oxide synthase, guanylyl cyclase, and tyrosine kinase but not by calmodulin inhibition. Flutamide treatment attenuated the development of hypertension in mouse renin transgenic rats with the tfm mutation. Flutamide produces direct vasodilation by inducing release of NO from the endothelium and causes subsequent activation of soluble guanylyl cyclase in an active androgen receptor independent manner. This response may contribute to the observed antihypertensive actions of flutamide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802502     DOI: 10.1007/s00109-003-0449-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  33 in total

Review 1.  Calcium-dependent and calcium-independent activation of the endothelial NO synthase.

Authors:  I Fleming; J Bauersachs; R Busse
Journal:  J Vasc Res       Date:  1997 May-Jun       Impact factor: 1.934

2.  Alterations in blood pressure and heart rate variability in transgenic rats with low brain angiotensinogen.

Authors:  O Baltatu; B J Janssen; G Bricca; R Plehm; J Monti; D Ganten; M Bader
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

3.  Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats.

Authors:  Ovidiu Baltatu; Cécile Cayla; Radu Iliescu; Dmitrii Andreev; Michael Bader
Journal:  Hypertension       Date:  2002-12-16       Impact factor: 10.190

Review 4.  Signal transduction of eNOS activation.

Authors:  I Fleming; R Busse
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

5.  Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action.

Authors:  Richard D Jones; Kate M English; Peter J Pugh; Alyn H Morice; T Hugh Jones; Kevin S Channer
Journal:  J Cardiovasc Pharmacol       Date:  2002-06       Impact factor: 3.105

6.  Response of the intact canine left ventricle to increased afterload and increased coronary perfusion pressure in the presence of coronary flow autoregulation.

Authors:  M K Karunanithi; J A Young; W Kalnins; S Kesteven; M P Feneley
Journal:  Circulation       Date:  1999-10-05       Impact factor: 29.690

7.  Clinical signs of androgen excess as risk factors for coronary artery disease.

Authors:  R A Wild; B Grubb; A Hartz; J J Van Nort; W Bachman; M Bartholomew
Journal:  Fertil Steril       Date:  1990-08       Impact factor: 7.329

8.  Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats.

Authors:  J Bohlender; J Ménard; O Edling; D Ganten; F C Luft
Journal:  Am J Physiol       Date:  1998-05

9.  Testosterone relaxes rabbit coronary arteries and aorta.

Authors:  P Yue; K Chatterjee; C Beale; P A Poole-Wilson; P Collins
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

10.  Testosterone causes direct relaxation of rat thoracic aorta.

Authors:  C E Costarella; J N Stallone; G W Rutecki; F C Whittier
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

View more
  4 in total

1.  Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.

Authors:  Y Wang; J-Q Li; C Shao; C-H Shi; F Liu; Z-Y Yang; J-X Qiu; Y-M Li; Q Fu; W Zhang; W Xue; Y-H Lei; J-Y Gao; J-Y Wang; X-P Gao; J-L Yuan; T-Y Bao; Y-T Zhang
Journal:  Ir J Med Sci       Date:  2011-07-05       Impact factor: 1.568

2.  Antiandrogen pretreatment alters cocaine pharmacokinetics in men.

Authors:  Rinah T Yamamoto; Christian J Teter; Tanya L Barros; Elissa McCarthy; Crystal Mileti; Trisha Juliano; Carissa L Medeiros; Alison Looby; Melissa A Maywalt; Jane F McNeil; David Olson; Gopinath Mallya; Scott E Lukas; Perry F Renshaw; Marc J Kaufman
Journal:  J Addict Med       Date:  2007-12       Impact factor: 3.702

3.  Non-genomic vasorelaxant effects of 17β-estradiol and progesterone in rat aorta are mediated by L-type Ca2+ current inhibition.

Authors:  Elisa Cairrão; Ezequiel Alvarez; João Miguel Carvas; Antonio Jose Santos-Silva; Ignacio Verde
Journal:  Acta Pharmacol Sin       Date:  2012-04-02       Impact factor: 6.150

4.  Testosterone and cholesterol vasodilation of rat aorta involves L-type calcium channel inhibition.

Authors:  E Alvarez; E Cairrão; M Morgado; C Morais; I Verde
Journal:  Adv Pharmacol Sci       Date:  2010-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.